Literature DB >> 11095449

Estrogen priming effect on growth hormone (GH) provocative test: a useful tool for the diagnosis of GH deficiency.

A S Martínez1, H M Domené, M G Ropelato, H G Jasper, P A Pennisi, M E Escobar, J J Heinrich.   

Abstract

We have studied the effect of estradiol (E2) on the GH-insulin-like growth factor (GH-IGF) axis in 15 prepubertal GH deficiency (GHD) children and 44 prepubertal or early pubertal children with idiopathic short stature (SS). All of them received a daily dose of micronized E2 (1 or 2 mg) or placebo, for 3 days, before a sequential arginine-clonidine test. In SS children, GH maximal responses were 17.8+/-10.9 on placebo and 27.9+/-14.5 microg/L on estrogen (P < 0.0001). The lower 95% confidence limits for GH maximal response changed from 3.7 microg/L (without E2) to 8.3 microg/L (on E2). In GHD children, no significant stimulatory effect of estrogen on GH levels was observed. After placebo, a cut-off limit of 3.7 microg/L (the lower 95% confidence interval limit) resulted in 73% sensitivity, 95% specificity, and an overall 90% diagnostic efficiency. After E2, a cut-off limit of 8.3 microg/L resulted in a sensitivity of 87%, a specificity of 98%, and a diagnostic efficiency of 95%. After placebo, 68% of SS showed normal IGF-I levels, and the mean did not change on E2 (13.7+/-6.3 vs. 14.3+/-6.8 nmol/L, not significant). In 93% of SS, IGF binding protein (IGFBP)-3 levels were normal during placebo. On E2, mean IGFBP-3 did not change (2.63+/-0.70 vs. 2.70+/-0.70 mg/L, not significant). In 14 of 15 GHD patients, IGF-I values were below normal on placebo, and the mean of the group did not change after E2. During placebo, 13 of 15 GHD children presented low IGFBP-3 values. During E2, there was a small significant increase in IGFBP-3 values (1.06+/-0.58 vs. 1.20+/-0.69 mg/L, P < 0.02). The highest diagnostic efficiencies for IGF-I and IGFBP-3 were observed during placebo (75% and 91%, respectively). We conclude that GH stimulation tests after E2 priming had the highest diagnostic efficiency. Our findings suggest that the effect of estrogen priming on GH stimulated levels, by reducing the number of false nonresponders, might be useful to better discriminate between normal and abnormal GH status in SS children.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11095449     DOI: 10.1210/jcem.85.11.6928

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  25 in total

1.  Case Report: The Specter of Untreated Congenital Hypothyroidism in Immigrant Families.

Authors:  Elwaseila Hamdoun; Peter Karachunski; Brandon Nathan; Melissa Fischer; Jane L Torkelson; Amy Drilling; Anna Petryk
Journal:  Pediatrics       Date:  2016-04-14       Impact factor: 7.124

Review 2.  Growth hormone treatment in non-growth hormone-deficient short children.

Authors:  S Loche; M R Casini; G M Ubertini; M Cappa
Journal:  J Endocrinol Invest       Date:  2005-02       Impact factor: 4.256

Review 3.  Diagnosis of growth hormone deficiency in childhood.

Authors:  Takara Stanley
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2012-02       Impact factor: 3.243

Review 4.  Diagnosis, Genetics, and Therapy of Short Stature in Children: A Growth Hormone Research Society International Perspective.

Authors:  Paulo F Collett-Solberg; Geoffrey Ambler; Philippe F Backeljauw; Martin Bidlingmaier; Beverly M K Biller; Margaret C S Boguszewski; Pik To Cheung; Catherine Seut Yhoke Choong; Laurie E Cohen; Pinchas Cohen; Andrew Dauber; Cheri L Deal; Chunxiu Gong; Yukihiro Hasegawa; Andrew R Hoffman; Paul L Hofman; Reiko Horikawa; Alexander A L Jorge; Anders Juul; Peter Kamenický; Vaman Khadilkar; John J Kopchick; Berit Kriström; Maria de Lurdes A Lopes; Xiaoping Luo; Bradley S Miller; Madhusmita Misra; Irene Netchine; Sally Radovick; Michael B Ranke; Alan D Rogol; Ron G Rosenfeld; Paul Saenger; Jan M Wit; Joachim Woelfle
Journal:  Horm Res Paediatr       Date:  2019-09-12       Impact factor: 2.852

5.  Early retesting by GHRH + arginine test shows normal GH response in most children with idiopathic GH deficiency.

Authors:  C Bizzarri; S Pedicelli; B Boscherini; G Bedogni; M Cappa; S Cianfarani
Journal:  J Endocrinol Invest       Date:  2014-11-07       Impact factor: 4.256

6.  Needle-Free and Needle-Based Growth Hormone Therapy in Children: A Pooled Analysis of Three Long-Term Observational Studies.

Authors:  Tilman R Rohrer; Sabine Ceplis-Kastner; Norbert Jorch; Hermann L Müller; Roland Pfäffle; Thomas Reinehr; Annette Richter-Unruh; Claudia Weißenbacher; Paul-Martin Holterhus; Dr Sabine Clips-Kastner Ferring Arzneimittel GmbH
Journal:  Horm Res Paediatr       Date:  2019-03-05       Impact factor: 2.852

7.  Adult height in children with short stature and idiopathic delayed puberty after different management.

Authors:  Stefano Zucchini; Malgorzata Wasniewska; Mariangela Cisternino; Mariacarolina Salerno; Lorenzo Iughetti; Mohamad Maghnie; Maria Elisabeth Street; Manuela Caruso-Nicoletti; Stefano Cianfarani
Journal:  Eur J Pediatr       Date:  2007-08-24       Impact factor: 3.183

8.  Blunted response to a growth hormone stimulation test is associated with unfavorable cardiovascular risk factor profile in childhood cancer survivors.

Authors:  Anna Petryk; K Scott Baker; Brigitte Frohnert; Antoinette Moran; Lisa Chow; Alan R Sinaiko; Lyn M Steffen; Joanna L Perkins; Lei Zhang; James S Hodges; Julia Steinberger
Journal:  Pediatr Blood Cancer       Date:  2012-09-21       Impact factor: 3.167

Review 9.  Growth hormone deficiency in children.

Authors:  Erick J Richmond; Alan D Rogol
Journal:  Pituitary       Date:  2008       Impact factor: 4.107

10.  The Biology of Stature.

Authors:  Youn Hee Jee; Jeffrey Baron
Journal:  J Pediatr       Date:  2016-03-26       Impact factor: 4.406

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.